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Abstract
Sulindac has antineoplastic effects on various cancer
cell lines; consequently, we assessed sulindac’s ef-
fects on laryngeal squamous cell carcinoma (SCC) cells
in vitro and in vivo. In vitro, SCC (HEP-2) cells treated
with various cyclooxygenase inhibitors or transfected
with constitutively active signal transducer and acti-
vator of transcription 3 (Stat3) or survivin vectors were
analyzed using Western blot analysis, annexin V assay,
and cell proliferation assay. In parallel, nude mice in-
jected subcutaneously with HEP-2 cells were either
treated intraperitoneally with sulindac or left untreated,
and analyzed for tumor weight, survivin expression,
and tyrosine-phosphorylated Stat3 expression. In vitro
studies confirmed the selective antiproliferative and pro-
apoptotic effects of sulindac, which also downregulated
Stat3 and survivin protein expression. Stat3 or survivin
forced expression partially rescued the antiproliferative
effects of sulindac. In vivo studies showed significant
repression of HEP-2 xenograft growth in sulindac-
treated mice versus controls, with near-complete reso-
lution at 10 days. Additionally, tumor specimens treated
with sulindac showed downregulation of phosphory-
lated tyrosine-705 Stat3 and survivin expression. Taken
together, our data suggest, for the first time, a spe-
cific inhibitory effect of sulindac on tumor growth and
survivin expression in laryngeal cancer, both in vitro
and in vivo, in a Stat3-dependent manner, suggesting a
novel therapeutic approach to head and neck cancer.
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Introduction
Head and neck squamous cell carcinoma (SCC) is a com-
mon cancer, with 40,000 new cases diagnosed annually in
the United States and a collective worldwide incidence of
500,000 new cases yearly, making it the sixth most common
cancer in the United States and the third most common
cancer worldwide [1,2]. However, over the past 50 years,
the prognosis for this cancer has not improved over the
50% 5-year survival rate [3].
The in vitro antineoplastic effects of nonsteroidal anti-
inflammatory drugs (NSAIDs) on various types of cancer, in-
cluding oral SCC cells, have been recognized for a number of
years [4–6]. In recent studies, the use of the NSAID sulindac
has shown an inhibitory effect on tumor growth in gastric, lung,
and colorectal cancers in nude mice, with a concomitant de-
crease in cell growth and an increase in apoptosis [7–12].
Furthermore, studies using sulindac in combination with other
anticancer drugs (cisplatin, paclitaxel, and docetaxel), epider-
mal growth factor receptor inhibitors, tumor necrosis factor-a,
mitomycin, or lactacystin (a proteasome inhibitor) have shown
a synergistic effect [12–19]. Although it is well known that
sulindac and other cyclooxygenase (COX) inhibitors exert anal-
gesic, antipyretic, and anti-inflammatory effects through the
inhibition of prostaglandins, the exact mechanism of their ability
to prevent cancer is still unknown [20,21].
The constitutive activation of signal transducer and activator
of transcription 3 (Stat3) is known to be associated with various
human cancers, including head and neck SCC, in which ab-
normal upstream tyrosine kinase signaling has been impli-
cated as the predicted culprit [22–27]. Oncogenic Stat3
signaling results in activation of target genes, including cyclin
D1, Bcl-2, and Bcl-xL, affecting cell proliferation, cell cycle,
tumor formation, and prevention of apoptosis [23–26].We have
previously shown that sulindac treatment of oral SCC cell lines
SCC4, SCC9, SCC15, and SCC25 causes a downregulation
of activated Stat3, with a concomitant inhibition of cell growth
and an increase in apoptosis [28]. Recent in vivo studies using
silencer siRNA for Stat3 have shown an inhibition of trans-
planted laryngeal tumor growth in mice, with a concomitant
increase in apoptosis [29].
Survivin, acting as an inhibitor of apoptosis, is normally
expressed in developing tissues, the thymus, basal colonic
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tissues, endothelial tissues, and neural stem cells, but not in
normally differentiated tissues [30]. It has been reported to
be overexpressed in lung, breast, colon, gastric, esopha-
geal, pancreatic, liver, bladder, uterine, ovarian, and brain
cancers, as well as in melanomas, lymphomas, leukemias,
neuroblastomas, sarcomas, and skin cancers, providing a
defect in the normal apoptotic pathway [30–32]. Further-
more, its expression has been detected in preneoplastic
lesions, suggesting a possible participation in the induction
of malignant transformation [30]. Current in vivo studies
in mice, using antisense oligodeoxynucleotides, dominant-
negative mutants combined with recombinant adenovirus,
or siRNA against survivin, have shown inhibition of trans-
planted tumor growth and induction of apoptosis in laryngeal,
liver, and hepatocellular carcinoma xenografts [30]. Recent
investigations have focused on the potential function of
survivin as a downstream target of Stat3 signaling [33–35].
Our recent studies have suggested that in oral cancer cell
lines SCC9 and SCC25, survivin may be a target of sulindac,
which mediates its antineoplastic effects [21].
Currently, no studies have explored the in vivo effects of
sulindac on cancer growth and the Stat3/survivin signaling
pathway in primary head and neck SCC in mouse models.
Here, we show for the first time the antiproliferative and pro-
apoptotic effects of sulindac using laryngeal SCC (HEP-2)
xenografts in nude mice, suggesting that sulindac may be a
potential therapeutic alternative for patients with SCC. In ad-
dition, we demonstrate that the antiproliferative effects of
sulindac on head and neck SCC may be mediated through
the downregulation of activated Stat3 and survivin in vivo.
Materials and Methods
Cell Lines and Cell Culture
All experiments were performed using the established
primary laryngeal SCC cell line HEP-2 (donated by Dr. Silvio
Gutkind; National Institutes of Health). Cells were cultured in
a 1:1 mix of Ham’s F12 and Dulbecco’s modified Eagle’s
medium (DMEM) with 10% fetal bovine serum, 100 U of peni-
cillin, 100 mg/ml streptomycin, and 0.4 g/ml hydrocortisone
(SigmaChemical Co., St. Louis, MO). The cells were cultured
at 37jC in a 5% CO2 air atmosphere. Cells were sub-
cultured using a disaggregation assay with trypsin (0.1%)
and ethylenediaminetetraacetic acid (EDTA; 0.01%) in
phosphate-buffered saline (PBS), pH 7.5.
Cells were grown in 6-well or 24-well plates at 5 
104 cells/well and grown to 80% confluence. The cells were
then either left untreated or treated with dimethyl sulfoxide
(DMSO) only or drug dissolved in DMSO. When DMSO
was used, its final concentration did not exceed 0.1%.
Drug Treatments
The following COX-2 inhibitors were used for in vitro
experiments:
Nonselective: 150 mM sulindac (Sigma Chemical Co.) and
150 mM indomethacin (Sigma Chemical Co.)
Selective: 150 mM nimesulide (Sigma Chemical Co.) and
150 mM celecoxib (Pfizer, New York, NY).
Transfection with Constitutively Active Stat3 Mutant
or Survivin Forced Expression Vectors
Vectors for constitutively active Stat3 mutant (c-Stat3)
and survivin forced expression, and corresponding control
vectors (clone name pCDNA 3.1 + Hygro constitutively active
C-terminus–tagged Stat3 and pcDNAIII myc-tagged survi-
vin, respectively) were generously donated by Dr. Silvio
Gutkind of the National Institutes of Health. These vectors
were created with the following primers: 5V BamHIII and
3V HindIII (for Stat3) or 3V EcoRI (for survivin), with resistance
to ampicillin. DNA were bacterially transformed using Bacto
agar (Difco, Sparks, MD), LB medium (Fisher, Hampton,
NH), and ampicillin (Sigma Chemical Co.), using GC5-
competent cells (Gene Choice, Frederick, MD). Plasmid
DNA purification was accomplished using HiSpeed Plasmid
Purification Maxi-Prep Kit (Qiagen, Valencia, CA). To deter-
mine the existence of a construct within purified DNA,
digestion with Bam and Eco enzymes (New England Bio-
laboratories, Ipswich, MA) was preformed. Cells were plated
in six-well plates using a density of 5  104 cells/well, al-
lowed to grow to 80% confluence, and treated with serum-
free medium for 24 hours. Expression or control mock
vectors were added at 0.4 mg/ml to 25 ml of Optimem
media (Invitrogen, Carlsbad, CA) and 4 ml of Plus Regent
(Invitrogen) and allowed to incubate for 15 minutes, whereas
1 ml of Lipofectamine 2000 reagent (Invitrogen) was added
to 25 ml of Optimem media and incubated for 15 minutes.
The vectors were combined with the Lipofectamine 2000 re-
agent and incubated for an additional 15 minutes at room
temperature. The combined mix was then added with 0.2 ml
of serum-free medium to the cells, which were incubated
at 37jC at 5% CO2 for 3 hours, followed by the addition
of a normal medium or various treatments for prescribed
times. Transfection efficiency was evaluated by immuno-
fluorescence analysis. Further analysis included Western
blot analysis and cell proliferation assay.
Cell Proliferation
Cells were plated in 24-well plates using a density of 5 
104 cells/well, allowed to grow to 80% confluence, and then
treated with serum-free medium for 24 hours. Subsequently,
a normal medium with DMSO (at a maximum concentration
of 0.1%); sulindac sulfide, indomethacin, nimesulide; or
celecoxib (all at 150 mM, dissolved in DMSO) was added to
a normal growth medium and incubated for 72 hours. Alter-
natively, cells were transfected with vectors for c-Stat3, sur-
vivin forced expression, or control mock vector for 24 hours
alone or followed by sulindac treatment for 72 hours. The cells
were removed enzymatically and counted using a Coulter
counter (Model ZI; Coulter, Miami, FL). The percentage of cell
growth was determined by setting as 100% the growth of
cells treated only with the vehicle (0.1% DMSO). All analyses
were performed in triplicate.
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Flow Cytometry and Annexin V Studies
Apoptosis was evaluated using annexin V–fluorescein
isothiocyanate methods. Cells were treated with either the
vehicle alone (DMSO at a maximum concentration of 0.1%)
or sulindac at 150 mM for 72 hours and washed with Hank’s
balanced salt solution, followed by lysis using trypsin (0.1%)
and EDTA (0.01%) in PBS at pH 7.5. The cells were washed
with normal medium and cold PBS, and resuspended in 1
binding buffer (BD-Pharmingen Biosciences, San Diego,
CA) Five microliters of annexin and 5 ml of propidium iodide
were added to the cells, vortexed, and incubated for 15 min-
utes in the dark. Finally, 400 ml of 1 binding buffer was
added, and samples were evaluated by flow cytometry.
Western Blot Analysis
Cell were treated with either normal medium with DMSO
(at a maximum concentration of 0.1%); 150 mM sulindac
sulfide for 72 hours; or c-Stat3 mutant, survivin forced ex-
pression vector, or control mock vector for 24 hours, followed
by sulindac treatment for 72 hours. The cells were washed
twice with ice-cold PBS, followed by lysis with radioimmuno-
precipation assay buffer (50 mM Tris pH 7.4, 150 mM NaCl,
1% Triton X-100, 1% deoxycholic acid, sodium salt, 0.1%
sodium dodecyl sulfate, 100 mg/ml phenylmethysulfonyl
fluoride, 1 mg/ml aprotinin, 1 mM dichlorodiphenyltrichloro-
ethane, and 1 mM sodium orthovanadate) for 10 minutes
at 4jC. The wells were scraped, and recovered cell prod-
ucts were centrifuged at 40,000g for 15 minutes at 4jC.
Recovered proteins were measured and equalized using
Bio-Rad Protein Assay (Bio-Rad Laboratories, Richmond,
CA) per manufacturer’s instructions. Tumor tissue samples
were placed in lysis buffer on ice for 10 minutes, crushed
and sonicated, and finally centrifuged to obtain the protein
supernatant. Western blot analysis was then performed
using a survivin polyclonal antibody (Abcam, Cambridge,
UK), or phosphorylated tyrosine-705 (p-tyr) Stat3 or total
Stat3 monoclonal antibodies (Cell Signaling, Beverly, MA).
Establishment and Treatment of SCC Tumor Xenografts
in Athymic nu/nu Mice
The HEP-2 cell line was used to induce xenografts in
6-week-old athymic (nu/nu) nude female mice. The animals
received food and water ad libitum and were housed in the
Association for Assessment and Accreditation for Animal
Care–approved Animal Facility of the University of Maryland
at Baltimore under the care and management of full-time
veterinarians and veterinary staff. All procedures involving
animals were approved by the Institutional Animal Care
and Use Committee. Exponentially growing cells were har-
vested, washed with PBS, and resuspended in DMEM, and
1  106 viable cells were transplanted subcutaneously into
the right flank of mice. For drug treatment, tumor-bearing
animals were randomly grouped (control, n = 5; test, n = 5)
and treated with sulindac sulfide (60 mg/kg). Treatment
schedule comprised a single injection per animal given intra-
peritoneally every other day (six injections in total). For
analysis, tumor weight was determined by converting
tumor volume (LW 2/2, where L andW represents the longest
length and the shortest width of the tumor, respectively) to
weight. At the end of the study period, animals were eu-
thanized for tissue retrieval, which was fixed for immuno-
histochemical analysis (4% paraformaldehyde overnight
before processing for paraffin embedding).
Immunohistochemistry
Paraffin-embedded tissue sections of tumor samples
(treated with sulindac or untreated) were deparaffinized,
immersed in ethanol 100% and 95%, and heated for antigen
retrieval in 0.01 M citrate buffer for 25 minutes in a pressure
cooker inside a microwave oven. After dehydration in hydro-
gen peroxide, the sections were incubated with primary anti-
bodies at room temperature for 1 hour. The applied antibody
was a monoclonal p-tyr Stat3 antibody (Cell Signaling) di-
luted at 1:500, monoclonal survivin antibody (Abcam) di-
luted at 1:100, or Ki-67 antibody (Dako, Carpinteria, CA)
diluted at 1:150. Standard streptavidin–biotin–peroxidase
complex method was employed to bind to the primary anti-
body along with multilink concentrated biotinylated anti-IgG
as secondary antibody. Reaction products were visualized
by counterstaining with the 3,3V-diaminobenzidine reagent
set (Kirkegaard and Perry Laboratories, Gaithersburg,
MD). Sections were counterstained with hematoxylin. As a
negative control, sections were treated with PBS, with the
omission of the primary antibody. Additionally, tumors were
stained with Harris’ hematoxylin (Harleco, Kansas City, MO)
and eosin (Sigma Chemical Co.) for microscopic evaluation.
Immunostains were reviewed by two independent eval-
uators (M.S. and N.N.). Immunohistochemical reactivity
for p-tyr Stat3, survivin, or Ki-67 was graded according to
the percentage of positive tumor cells (0, 0%; 1, < 20%; 2,
20–50%; 3, > 50%) and intensity of staining (, no staining;
w, weak; m, moderate; s, strong) compared to negative
control tissues.
Terminal Deoxynucleotidyl Transferase–Mediated
dUTP-Biotin End Labeling (TUNEL) Staining
Paraffin-embedded tissue sections of tumor samples
(treated with sulindac and untreated) were deparaffinized,
immersed in ethanol 100% and 95%, and heated for antigen
retrieval in 0.01 M citrate buffer for 10 minutes in a pressure
cooker inside a microwave oven. The tissues were rinsed in
PBS and labeled using 50 ml of a 9:1 solution of Label and
Enzyme solutions from the In Situ Cell Death Detection Kit,
Fluorescein (Roche Applied Sciences, Mannheim, Ger-
many), with appropriate controls labeled only with the Label
solution. The tissues were incubated for 1 hour at 37j in
a humidified atmosphere in the dark. The tissues were rinsed
in PBS and analyzed directly under a fluorescence micro-
scope with a detection range of 515 to 565 nm.
Statistical Analysis
For all measurements, as needed, a Student’s t test or
t-test was employed to assess the statistical significance of
treated groups versus control groups. A statistically sig-
nificant difference was considered to be present at P V .05.
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Results
Treatment with Sulindac, But Not Other COX
Inhibitors, Inhibits Cell Proliferation and Induces
Apoptosis in HEP-2 Cells
We first sought to study the in vitro antiproliferative effects
of sulindac on laryngeal SCC (HEP-2) cells and to examine
whether these effects are independent of COX-2 inhibition.
Treatment of HEP-2 cells with sulindac sulfide, the active
metabolite of sulindac, caused significant decreases in cell
proliferation (P V .05; versus control cells); in contrast, treat-
ment with selective or nonselective COX inhibitors (indo-
methacin, nimesulide, or celecoxib) did not significantly
affect HEP-2 cell proliferation (Figure 1A). The inhibitory ef-
fects of sulindac sulfide on cell growth were accompanied
by a 3.3-fold increase in apoptosis (Figure 1B), which was
statistically significant (P V .05).
In summary, treatment with sulindac, but not other COX
inhibitors, exerts in vitro cell growth– inhibitory and pro-
apoptotic effects on HEP-2 head and neck SCC cells.
Downregulation of Stat3 and Survivin Expression
By Sulindac Mediates Its Antiproliferative Effects
on HEP-2 Cells
Previous evidence has shown that constitutive activation
of Stat3 in cancer cell lines, including head and neck cell lines,
leads to cell proliferation, survival, and sustained growth,
through induction of downstream molecules such as sur-
vivin [23–26,33–35]. We then set out to determine whether
the in vitro effect of sulindac’s antineoplastic activity on
HEP-2 cells is also directly related to its inhibitory effect
on Stat3 signaling and subsequent downregulation of sur-
vivin expression.
First, the effects of sulindac treatment on p-tyr Stat3,
Stat3, and survivin expression of HEP-2 cells were deter-
mined by Western blot analysis. We observed that in HEP-2
cells, sulindac downregulates p-tyr and total Stat3, and sur-
vivin protein levels (Figure 2A). HEP-2 cells were then trans-
fected with either a flag-tagged constitutively active Stat3
vector (c-Stat3), a myc-tagged survivin vector, or a control
vector for 24 hours. Western blot analysis showed that
sulindac treatment caused significant decreases in the pro-
tein levels of p-tyr Stat3, Stat3, and survivin in cells treated
with the mock vector (Figure 2B). However, survivin forced
expression abrogated the effects of sulindac treatment on the
downregulation of the levels of this protein (Figure 2B).
Moreover, transfection with c-Stat3 reversed the effects of
sulindac on p-tyr and total Stat3 levels, as well as on survivin
protein expression (Figure 2B). In addition, the forced ex-
pression of survivin or transfection with c-Stat3 mutant par-
tially rescued the cell proliferation of HEP-2 cells despite
sulindac treatment. Specifically, following sulindac treatment,
the cell proliferation rate of survivin-transfected cells (67.4%)
and active Stat3-transfected cells (82.1%) was significantly
higher than that of similarly treated nontransfected (40.7%)
or mock vector–transfected (46.8%) cells (Figure 2C).
Therefore, transfection with c-Stat3 or survivin forced
expression is able to decrease the antineoplastic effects of
sulindac treatment, suggesting that the ability of sulindac to
repress survivin and Stat3 mediates, at least partially, its
effects on HEP-2 cancer cell growth.
Sulindac Reduces Xenograft Tumor Burden and Weight
Previous results suggesting an antiproliferative activity
of sulindac in head and neck cancer cells prompted us to
examine the potential clinical benefit of such drug for the
treatment of head and neck cancer patients. For that pur-
pose, athymic (nu/nu) nude female mice were injected sub-
cutaneously with HEP-2 cells in the right flank, allowing for
the development of subcutaneous tumors. Following tumor
formation, five mice were treated every other day (six doses
in total) with 60 mg/kg sulindac sulfide, whereas five control
mice were left untreated for the same period of time. Drug
toxicity, as assessed by animal weight loss, was minimal in
the sulindac-treated group (reduction < 5%) during the dura-
tion of the study period (results not shown). Sulindac-treated
tumors showed a considerable reduction in tumor burden
over 11 days of observation, compared with nontreated tu-
mors (Figure 3A). Tumor regression in treated animals was
observed for 19 days after the beginning of the treatment,
and inhibition of tumor growth was sustained for the duration
of the experiment (Figure 3, A–C). At the end of the study
(day 19), we observed that although the average weight of
vehicle-treated tumors was 1024 mg (an almost five-fold
increase), the sulindac-treated group demonstrated minimal
growth over the same period, with an average tumor weight
Figure 1. In vitro COX-independent effects of sulindac on HEP-2 tumor cell
proliferation and apoptosis. (A) Assessment of HEP-2 cell proliferation fol-
lowing 72 hours of treatment with the vehicle alone (0.1% DMSO; C) or with
COX inhibitor 150 M sulindac (Sul), 150 M indomethacin (Indo), 150 M
nimesulide (Nime), or 150 M celecoxib (Cele). The growth of control cells
(C) has been set to 100%. *Statistically significant (P V .05) differences
compared to control cells. (B) Annexin V assay in HEP-2 cells for a com-
parison of apoptosis following 72 hours of treatment with the vehicle alone
(0.1% DMSO; C) or with 150 M sulindac (Sul). *Statistically significant
(P V .05) differences compared to control cells.
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of 8 mg on day 19 (Figure 3C), consistent with continued
tumor regression over the same treatment period.
p-tyr Stat3 and Survivin Protein Levels Decrease
in Sulindac-Treated Xenografts
Excised tumors were further examined to determine his-
tologic characteristics and degree of differentiation. All
tumors demonstrated moderately differentiated SCC char-
acteristics; however, the tumors resected from sulindac-
treated animals showed decreased cellularity and mitotic
activity, and increased necrosis and number of apoptotic
bodies on hematoxylin and eosin (H&E) analysis, compared
to untreated control mice (Figure 4A, a and b). To confirm
the H&E findings, both apoptosis and proliferation assays
were preformed. A TUNEL assay confirmed an increase
of apoptosis in sulindac-treated animals compared to un-
treated control mice (Figure 4A, c and d ), whereas Ki-67
staining confirmed an increase in cell proliferation in un-
treated control mice tumors versus sulindac-treated animals
(Figure 4A, e and f ).
Next, an immunohistochemical expression analysis of
survivin and p-tyr Stat3 was evaluated in sulindac-treated
versus untreated mouse tumors. The untreated tumors
showed a strong expression (3S) of survivin (Figure 4B, a)
and a moderate expression (2M) of p-tyr Stat3 (Figure 4B, c),
whereas sulindac-treated tumors showed a diminished ex-
pression (1W) of survivin (Figure 4B, b) and failed to express
p-tyr Stat3 (Figure 4B, d ).
To further evaluate whether sulindac treatment reduces
the protein expression of p-tyr Stat3 and survivin in vivo, pro-
tein was extracted from tumors resected from nude mice.
Western blot analysis of tumor protein levels showed a down-
regulation of p-tyr Stat3 and survivin protein levels in sulindac-
treated tumors versus untreated control mice (Figure 4C).
Taken together, these results support the ability of sulin-
dac to downregulate Stat3 signaling and survivin expression
in vivo, which may provide a molecular explanation for its
potent in vivo anticancer properties.
Discussion
Aberrant constitutive activation of Stat3 signaling has been
well established in various cancers, including head and neck
cancer [23–27,33,36], where it is implicated in early tumor
Figure 2. The role of Stat3 and survivin in sulindac’s effects on HEP-2 cells. (A) In vitro effects of sulindac treatment on Stat3 and survivin expression. Western blot
analysis of p-tyr Stat3, total Stat3, or survivin expression in HEP-2 cells following treatment for 72 hours with the vehicle alone (0.1% DMSO) (lane 1; C) or with
150 M sulindac (lane 2; Sul). Actin was used as loading control. (B) Effects of transfection with constitutively active Stat3 (c-Stat3) or survivin forced expression on
sulindac’s ability to modulate Stat3 and survivin protein expression. Western blot analysis of p-tyr Stat3, total Stat3, or survivin protein expression in HEP-2 cells,
following treatment with the vehicle alone (0.1% DMSO) (lane 1); sulindac (150 M) for 72 hours (lane 2); C-terminus Flag epitope– tagged c-Stat3 vector for
24 hours only (lane 3); myc-tagged survivin vector for 24 hours only (lane 4); control mock vector for 24 hours only (lane 5); C-terminus Flag epitope– tagged
c-Stat3 vector for 24 hours followed by sulindac (150 M) for 72 hours (lane 6); myc-tagged survivin vector for 24 hours followed by sulindac (150 M) for 72 hours
(lane 7); or control mock vector for 24 hours followed by sulindac (150 M) for 72 hours (lane 8). Actin was used as loading control. (C) Effects of transfection with
c-Stat3 or survivin forced expression on sulindac’s antiproliferative ability. Assessment of HEP-2 cell proliferation following treatment with the vehicle alone (0.1%
DMSO; C); sulindac (150 M) over 72 hours (Sul); expression vector for c-Stat3 (S3V) for 24 hours; expression vector for survivin (SVV) for 24 hours; control vector
(CV) for 24 hours; combined treatment of c-Stat3 vector for 24 hours followed by sulindac (150 M) for 72 hours (S3V-Sul); combined treatment of survivin vector
for 24 hours followed by sulindac (150 M) for 72 hours (SVV-Sul); or combined treatment of control vector for 24 hours followed by sulindac (150 M) for 72 hours
(CV-Sul). The cell proliferation of control cells treated with 0.1% DMSO has been set to 100%. *Statistically significant (P V .05) differences compared to control
cells. **Statistically significant (P V .05) differences compared to nontransfected or control vector – transfected cells treated with sulindac.
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formation and progression and correlates with adverse prog-
nosis [24,36]. Recent studies in gastric carcinomas and
primary effusion lymphomas have shown that Stat3 inhibition
results in the downregulation of survivin expression and its
proproliferative and antiapoptotic effects, implicating survivin
as a significant downstream target of Stat3 signaling in
cancer [33,34]. This notion is corroborated by the recent
demonstration of the in vivo downstream effects of aberrant
Stat3 activation on survivin expression in hepatoma cells,
endothelial cells, and laryngeal tumors [37–39]. Therefore,
novel therapeutic approaches with the ability to target aber-
rant Stat3/survivin signaling in cancer hold great promise.
In this regard, we have previously observed that sulindac,
a nonselective COX inhibitor with antiproliferative and pro-
apoptotic effects, causes downregulation of Stat3 tyrosine
phosphorylation and protein expression, also inhibiting sur-
vivin expression in oral cancer cell lines [21,28]. Other in-
vestigators have established that sulindac and other COX
inhibitors decrease survivin expression in colorectal carci-
noma, breast cancer, non–small cell lung cancer, and lym-
phoma [35,40–42]. However, the in vivo ability of sulindac to
inhibit tumor growth in head and neck cancer has not been
evaluated. This, combined with the lack of effective treat-
ment strategies for head and neck SCC, prompted us to
examine the role of sulindac in head and neck SCC, with the
aim of assessing the potential in vivo efficacy of this drug
and to elucidate its molecular mechanisms of function.
Using the highly tumorigenic HEP-2 cell line [29], we dem-
onstrated that laryngeal SCC cells were sensitive to in vitro
treatment with sulindac (but not other COX inhibitors), ex-
hibiting significant reduction of cell proliferation and survival.
These effects were accompanied by downregulation of the
protein levels of active and total Stat3 and survivin, which
appeared to be, at least partially, responsible for sulindac’s
in vitro anticancer properties. When HEP-2 cells were trans-
fected with constitutively active Stat3 or subjected to sur-
vivin forced expression, there was a rescue effect on Stat3/
survivin signaling, cancer cell proliferation, and survival de-
spite sulindac treatment. These in vitro observations sup-
port the specific antineoplastic effects of sulindac on
laryngeal SCC cells, highlighting Stat3 and survivin as sig-
nificant targets for this drug. Interestingly, this effect of Stat3
downregulation on survivin expression is a supposed direct
effect, as there is evidence that the promoter area of sur-
vivin contains a Stat3-binding element that directly regulates
its expression [43].
We also determined the in vivo effectiveness of sulindac
against laryngeal SCC cells by showing that sulindac was
able to significantly reduce tumor burden and weight in mice
bearing xenograft HEP-2 tumors. Moreover, sulindac elimi-
nated the protein expression of activated Stat3 and severely
decreased the protein levels of survivin in tumor xenografts,
suggesting that downregulation of Stat3/survivin signaling
may account for the in vivo effects of sulindac on laryngeal
SCC xenograft tumors. Therefore, both in vitro and in vivo,
sulindac-induced Stat3 and survivin downregulation may
be directly linked to the inhibition of cancer cell proliferation
and tumor growth.
Figure 3. Effects of sulindac on HEP-2 xenografts tumor volume and weight. (A and B) Growth inhibition (as assessed by tumor volume and weight) of
subcutaneously transplanted HEP-2 xenografts treated with sulindac (60 mg/kg) every other day over a period of 11 consecutive days followed by 8 days of follow-
up evaluation versus untreated control animals. The difference in tumor volume and weight between sulindac-treated and untreated tumors was statistically
significant (P V .05) on day 3 and on all subsequent time points for tumor volume and weight. (C) Representative mice showing untreated (left) and sulindac
(60 mg/kg)– treated (right) tumors on day 19.
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Demonstration of the immunohistochemical expression
of the tyrosine-phosphorylated (active) form of Stat3 and sur-
vivin in the tumor cells of laryngeal SCC xenografts corre-
lates well with previous studies showing the overexpression
of activated Stat3 and survivin in head and neck SCC tu-
mors [21,26,32,44,45]. It is possible that assessment of the
pretreatment levels of Stat3 and/or survivin expression in
tumors may facilitate the selection of the most effective
treatment. To this end, future studies should attempt to
correlate the protein levels of these molecules with the ef-
ficacy of sulindac and other Stat3-targeting and/or survivin-
targeting therapeutic regimens. Moreover, further animal
studies are needed to determine the possible additive or
synergistic effects of sulindac, along with other anticancer
modalities, in controlling tumor formation and the progression
of head and neck SCC. In addition, the effects of sulindac
treatment on angiogenesis and downstream effectors of
survivin need to be elucidated [46–50].
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